Revive Therapeutics Provides an Update on its Psilocybin-Based Pharmaceutical Program

TORONTO, April 29, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV),…

Revive Therapeutics Partners with Complete Phytochemical Solutions to Advance Research Initiatives for Psilocybin-Based Pharmaceutical Products

TORONTO, April 17, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV),…

Revive Therapeutics Engages Novotech as Asia-Pacific CRO for Bucillamine in the Treatment of Infectious Diseases

TORONTO, April 08, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV),…

Revive Therapeutics Announces Filing of FDA Pre-IND Meeting

TORONTO, April 03, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV),…

Revive Therapeutics Provides Corporate Update on its COVID-19 and Infectious Diseases Programs

Revive Therapeutics Ltd. (CSE: RVV) TORONTO, March 30, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive”…

Revive Therapeutics Engages Pharma-Olam and Strengthens Infectious Diseases Clinical Development Team to Advance U.S. FDA Clinical Study for COVID-19

Revive Therapeutics Ltd. (CSE: RVV) TORONTO, March 25, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive”…

Revive Therapeutics Appoints Dr. David Boulware, MD, as Scientific Advisor for Infectious Diseases including COVID-19

Revive Therapeutics Ltd. (CSE: RVV) TORONTO, March 24, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive”…

RVV | A penny stock that may have an Influenza / Covid-19 treatment in its hands ?

For several weeks, the world has been upside down due to the rapid spread of a…

Revive Therapeutics Explores the Use of Bucillamine as a Novel Treatment for Infectious Diseases including COVID-19

TORONTO, March 20, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV),…

Revive Therapeutics Announces Closing of Brokered Private Placement

Revive Therapeutics just release the closing of brokered private placement despite the difficult pandemic conditions :…

Revive Announces Closing of the Acquisition of Psilocin Pharma Corp.

TORONTO, March 05, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”), a company…

Revive Therapeutics | RVV Provides Update on its Clinical Development Plan for Cannabidiol in the Treatment of Autoimmune Hepatitis

TORONTO, Feb. 18, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”), a company…